FDA 483 at Houston RX: 14 Sterility Findings Behind Recalled Compounded Tirzepatide Vials
An FDA six-day inspection of Houston RX LLC, a North Houston compounding pharmacy, produced a Form 483 with 14 observations about sterile injectable production — including aseptic work performed with exposed skin, reversed cleanroom pressure, microbial growth recovered in an ISO 5 hood, and active-ingredient certificates marked for research and development only — and the firm subsequently recalled 64 vials of compounded tirzepatide with niacinamide for lack of sterility assurance. The inspection ran on six days between August 20 and August 28, with the Form 483 issued on the final day, according to the FDA inspection report summarized by Medical Daily.
The case matters to the compounded GLP-1 segment of the peptide therapy market because compounded tirzepatide and semaglutide are not FDA-approved products, and the patients receiving them through telehealth programs, clinics and med spas generally cannot distinguish a sterile vial from a compromised one by inspection. For clinics, telehealth operators and peptide suppliers, the document is a concrete example of what sterility-assurance failures look like at the facility level — and of the documentation trail buyers are expected to check before a vial reaches a patient.
What the FDA inspection actually documented
The Form 483 records observations made during the inspection; it states that the observations do not represent a final FDA determination about compliance, and the company can respond or correct them. Medical Daily reported that it could not locate a public response from Houston RX. The findings should therefore be read as inspectors’ documented observations, not as an adjudicated compliance outcome.
According to the inspection report, the first observation states that personnel performed aseptic manipulations with exposed hair or skin, and that an operator working inside the ISO 5 hood — the cleanest workspace — had exposed forehead skin while stoppering freshly filled semaglutide-niacinamide vials. Other observations describe cleanroom air: pressure readings between the buffer room and the less clean anteroom were all negative from July 10 to August 21, a reversal that can allow dirtier air to drift toward sterile work, and lots manufactured during that period were released.
The report further states that on August 3 the pharmacy recovered microbial growth in the ISO 5 hood after filling a lot of tirzepatide-niacinamide, and that no investigation followed because the firm’s action level was deemed inappropriate by the FDA; that lot was released and partially distributed. Inspectors also documented that staff pressed stoppers into vials by hand, that vials were finished outside the clean area, and that beakers, stir bars and graduated cylinders used for sterile drugs were not sterilized or depyrogenated. A ceiling vent just outside the cleanroom had water stains and what appeared to be mold, and was dripping condensate on one inspection day.
The ingredient-grade problem: research certificates and supplement-grade niacinamide
Perhaps the most consequential observations for the peptide supply chain concern what went into the vials. Certificates for the tirzepatide and semaglutide active ingredients were marked for research and development only, and a sermorelin ingredient was labeled for scientific research use. The niacinamide used in all of the pharmacy’s GLP-1 formulas met a dietary supplement standard rather than a pharmaceutical one, and several ingredients were not stored at the temperatures stated on their labels.
This is a distinction that industry buyers are routinely told to verify. A research-use designation indicates a stated research purpose rather than authorization for clinical treatment, and it does not by itself verify identity, purity, sterility or suitability for human administration. Similarly, a certificate of analysis reports specified analytical results for a material or batch; it does not independently establish clinical safety, efficacy, sterility for a particular use, or regulatory approval. In this case, the documented gap was not a disputed test result but a mismatch between the grade declared on supplier documentation and the use to which the material was put.
For sourcing teams, the practical lesson is that grade declarations on certificates belong in the qualification file alongside HPLC and LC-MS data, impurity profiles and storage conditions. Platforms that track peptide supply-chain documentation, such as 多肽供应链资源网, exist precisely because that verification work is difficult to do one purchase order at a time.
Key numbers from the inspection and recall record
| Item | Figure | Status / source |
|---|---|---|
| Form 483 observations | 14 | FDA inspection report (Form 483) |
| Inspection days | 6 (August 20–28) | FDA inspection report |
| Recalled tirzepatide-niacinamide vials | 64 vials, 2 mL, 20 mg/2 mg per mL; Class II | FDA enforcement records via MedShadow roundup |
| Recalled sermorelin vials | 7 vials; Class II | FDA enforcement records via MedShadow roundup |
| Adverse event reports, compounded semaglutide | 990 (as of May 31, 2026) | FDA unapproved GLP-1 page |
| Adverse event reports, compounded tirzepatide | More than 730 (as of May 31, 2026) | FDA unapproved GLP-1 page |
| Median all-in price, compounded tirzepatide | $222 per month across 14 online programs | NexLife survey, company-compiled, not independently verified |
| Median all-in price, compounded semaglutide | $175 per month across 16 online programs | NexLife survey, company-compiled, not independently verified |
Why this matters for peptide therapy clinics and telehealth
The recall itself is narrow: Houston RX began recalling 64 two-milliliter vials of tirzepatide-niacinamide 20 mg/2 mg per mL on September 25, classified by the FDA as Class II, and also recalled seven vials of compounded sermorelin, a growth hormone-releasing peptide, citing a lack of process control, likewise Class II. No illnesses linked to the recalled vials have been publicly reported.
The wider relevance lies in the operating model the observations describe. Clinics and telehealth platforms that source compounded GLP-1 products from 503A or 503B compounding pharmacies depend on the pharmacy’s sterility controls, because the clinic does not test vials before injection. When a supplier’s environmental monitoring, pressure differentials, equipment preparation and ingredient qualification break down, the clinic inherits the risk without any visible signal. That is why supplier qualification in this segment increasingly turns on inspection history, recall records and batch documentation rather than price alone.
Industry observers note that the FDA’s adverse-event tally — 990 reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide as of May 31, 2026 — is often cited as evidence of risk, but the agency’s own framing is that the reports alone do not prove the drugs caused the problems, and that events are likely underreported. The Houston RX file does not add a confirmed case to that count; it documents the conditions under which a sterility-assurance failure can occur.
Research and market context: price, demand and the oversight trade-off
Compounded GLP-1 products compete largely on cost. A NexLife price survey, compiled by the telehealth company and not independently verified, found a median all-in price of $222 per month for compounded tirzepatide across 14 online programs and $175 for compounded semaglutide across 16. Those figures sit well below branded list pricing, and cost is widely described as a driver of demand — an assertion that is plausible but not demonstrated by the survey data, which contains no demand measurement.
The trade-off is oversight. Compounded drugs are not FDA-approved, and the Houston RX case is not isolated: other pharmacies, including Carolina Infusion in Ridgeland, South Carolina, and Apothecary Pharma in Cary, North Carolina, have had recent sterility-related recalls of compounded GLP-1 products, according to a MedShadow Foundation roundup cited in the reporting. For research-peptide suppliers and clinics operating adjacent to this market, the pattern reinforces a compliance boundary worth stating plainly: research-use peptides are supplied for laboratory work and must not be represented as approved treatments, and any human use of a prescription peptide requires prescription and medical supervision.
From a manufacturing standpoint, the observations map onto standard sterile-injection controls that contract manufacturers and compounding operations are expected to maintain: validated aseptic technique with proper gowning, maintained positive pressure cascades from cleaner to less clean spaces, defined and justified environmental-monitoring action levels with investigation and batch disposition decisions, depyrogenation of product-contact equipment, and pharmaceutical-grade excipients with documented storage conditions. Each of these is a documented, auditable control rather than a matter of inspection judgment.
What comes next
Any further FDA action, such as a warning letter, would depend on the agency’s review of the firm’s response and corrective actions; the Form 483 is the opening of that process, not its conclusion. Readers tracking the segment should watch three things: whether Houston RX publishes a response or additional recall notices, whether the FDA’s unapproved GLP-1 enforcement page adds related actions, and whether clinics and telehealth platforms adjust supplier-qualification criteria in response.
This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com. PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates.
FAQ
What did the FDA find at Houston RX?
Inspectors documented 14 observations on a Form 483, including aseptic work with exposed skin, negative pressure between the buffer room and anteroom from July 10 to August 21, microbial growth recovered in an ISO 5 hood on August 3, hand-stoppering, non-depyrogenated equipment, a mold-stained ceiling vent, research-and-development-only certificates for tirzepatide and semaglutide, and supplement-grade niacinamide.
Were the recalled vials contaminated?
The recall reason is a lack of assurance of sterility, not a confirmed finding of contamination in the recalled vials, and no illnesses linked to them have been publicly reported.
Does a Form 483 mean the pharmacy broke the law?
No. The document states that the observations do not represent a final FDA determination about compliance, and the company can respond or correct them.
Are compounded tirzepatide and semaglutide FDA-approved?
No. Compounded drugs are not FDA-approved, and their quality depends on the compounding pharmacy’s controls and the applicable regulatory pathway.